Skip to main content
Sickle cell disease drug crizanlizumab by Novartis gains FDA approval
11/18/2019

Novartis' drug Adakveo, or crizanlizumab-tmca, was approved by the FDA as a treatment for patients aged 16 and older with sickle cell disease patients to lessen the frequency of vaso-occlusive crisis.

Full Story: